Can Your Protocol Flex? The Importance Of Adaptive Trial Designs In Precision Oncology Studies

By Abie Ekangaki

Even with significant advances in the understanding of the genetic and molecular mechanisms, cancer remains as one of the most scientifically complex and dynamic diseases. Today, only 10% of approved oncology drugs demonstrate an overall survival benefit. As research continues to press forward, adaptive trial designs have become more common over time, causing the industry to shift in how early-phase oncology studies are conducted.

Discover how these designs are working to limit the number of patients exposed to ineffective doses or treatments and accelerate detection of efficacy signals to improve the likelihood of trial success.